Surgical Sperm Retrieval: Effective Infertility Treatment for Men — Cost, Top Hospitals & Success Rates | MyMedicPlus

Surgical sperm retrieval (SSR) encompasses a group of minimally invasive urological procedures designed to obtain viable spermatozoa directly from the testis or epididymis in men who have no sperm in their ejaculate (azoospermia) or insufficient sperm for natural conception. Retrieved sperm are then used for intracytoplasmic sperm injection (ICSI) — a variant of IVF in which a single sperm is injected directly into an oocyte — as the low yield of surgically retrieved sperm precludes conventional IVF insemination techniques.

Azoospermia affects approximately 1% of all men and 10–15% of infertile men. It is classified as obstructive azoospermia (OA — normal sperm production in the testis but a blockage preventing sperm from reaching the ejaculate) or non-obstructive azoospermia (NOA — intrinsic testicular failure with severely impaired or absent spermatogenesis). The cause determines both the most appropriate SSR technique and the probability of successful sperm retrieval: OA patients have near-universal sperm retrieval success (95–100%); NOA patients have sperm retrieval rates of 30–60% with microsurgical techniques.

Causes of OA include: prior vasectomy (most common cause in developed countries); congenital bilateral absence of the vas deferens (CBAVD — typically associated with CFTR mutations and cystic fibrosis spectrum), obstructive epididymal or ejaculatory duct pathology, and previous groin or scrotal surgery. NOA causes include Klinefelter syndrome (47,XXY), cryptorchidism, cancer treatment (chemotherapy, pelvic radiotherapy), varicocele, and idiopathic testicular failure. NOA patients should undergo hormonal evaluation (FSH, LH, testosterone) and Y chromosome microdeletion testing before proceeding to SSR, as AZFa or AZFb deletions predict near-zero sperm retrieval and would spare patients futile surgery.

Surgical sperm retrieval is indicated for: obstructive azoospermia from any cause where reconstruction (vasectomy reversal, vasoepididymostomy) is not desired or has failed; non-obstructive azoospermia where sperm production is severely impaired but focal areas of spermatogenesis may still exist; severe oligozoospermia (extremely low sperm count in the ejaculate) insufficient for IVF where testicular sperm may have better quality; spinal cord injury and ejaculatory failure (where electroejaculation yields inadequate or no sperm); and fertility preservation prior to cancer treatment (pre-TESE with sperm cryopreservation before chemotherapy or radiotherapy).

SSR combined with ICSI is the only pathway to biological fatherhood for men with severe NOA who wish to use their own genetic material. For men with complete AZFa or AZFb Y chromosome deletions, use of donor sperm is the only viable alternative as SSR invariably fails in these patients.

Men with confirmed azoospermia on at least two semen analyses (3-month interval recommended) performed by an accredited andrology laboratory, with a female partner appropriate for ICSI, are candidates for SSR. Pre-SSR workup includes: hormonal assessment (FSH, LH, total testosterone, prolactin); testicular volume assessment (orchidometer or ultrasound); karyotype; and Y chromosome microdeletion analysis (AZF deletions a, b, c). Genetic counselling should precede SSR in men with genetic causes of azoospermia (Klinefelter syndrome, CFTR mutations, Y microdeletions) to discuss implications for offspring.

General anaesthetic fitness for the planned procedure and absence of active scrotal infection are prerequisites. Men with NOA and FSH exceeding 3 times the upper limit of normal, small testicular volume, and negative FSH receptor polymorphisms have lower retrieval probability but may still retrieve sperm with microsurgical TESE (micro-TESE). Cystic fibrosis carrier status in both partners should be assessed before ICSI using sperm from CBAVD patients, as the offspring has a 50% chance of being a CF carrier and a 25% chance of being affected if both parents are CF carriers.

Percutaneous Epididymal Sperm Aspiration (PESA) — a fine needle inserted through the scrotal skin into the epididymis under local anaesthesia, aspirating sperm-containing fluid — is suitable for obstructive azoospermia with dilated epididymides; fast, inexpensive, no incision required; repeat procedure possible. Microscopic Epididymal Sperm Aspiration (MESA) — open epididymal microdissection under magnification — provides larger quantities of high-quality sperm for cryopreservation; performed under general or spinal anaesthesia.

Testicular Sperm Extraction (TESE) — open biopsy through a small scrotal incision removing multiple testicular tissue pieces — is used for both OA and NOA; multiple biopsy approach increases NOA retrieval rates. Microdissection TESE (micro-TESE) — operating microscope-guided exploration of the entire testis identifying dilated seminiferous tubules with active spermatogenesis (appearing opaque and larger under 20–25x magnification) — achieves the highest NOA sperm retrieval rates (40–60%) while preserving testicular tissue. Micro-TESE is the gold standard for NOA and is associated with the lowest rate of testicular damage (smallest excised tissue volume). Testicular Sperm Aspiration (TESA) — needle aspiration of the testicular parenchyma — is simpler than open TESE but yields smaller samples; appropriate for OA, less reliable for NOA. Shared decision-making between the patient and specialist ensures the chosen modality aligns with individual anatomy, comorbidities, risk tolerance, and personal goals. A formal consultation with a board-certified specialist, review of pre-treatment imaging or investigation results, and multidisciplinary team input for complex cases are standard practice before finalising the treatment plan.

Surgical sperm retrieval combined with ICSI provides the only biological fatherhood option for men with azoospermia using their own sperm. Sperm retrieval success rates with micro-TESE for NOA are 40–60% overall, rising to 70–80% in Klinefelter syndrome (due to focal spermatogenesis that persists in individual tubules). Once sperm is retrieved, ICSI fertilisation rates are 60–70%, comparable to ICSI with ejaculated sperm. Live birth rates per ICSI cycle using surgically retrieved sperm are 25–40% per fresh transfer, equivalent to standard ICSI.

Cryopreservation of surgically retrieved sperm allows multiple ICSI cycles from a single retrieval procedure, avoiding the need for repeat surgery. Advance testicular sperm banking — performed before cancer treatment — preserves future fertility options that would otherwise be lost. Micro-TESE preserves testicular function better than standard multiple-biopsy TESE by minimising tissue excision and sparing testicular blood supply.

PESA and TESA carry low procedural risk: minor haematoma (3–5%), infection (less than 1%), and occasional epididymal fibrosis limiting future procedures. Open TESE and micro-TESE carry risks of haematoma (3–8%), scrotal infection (less than 2%), and — most importantly — testicular atrophy and long-term reduction in testosterone production from damage to the intratesticular vasculature. Multiple-biopsy TESE has been associated with reduced testosterone levels and Leydig cell function in 20–30% of patients at 12 months; micro-TESE minimises this risk by reduced tissue excision under optical magnification.

Failure to find sperm in NOA (40–60% of cases) is a significant psychological risk — couples must be counselled about this possibility before surgery and advised to have a donor sperm consent arrangement as a backup plan. ICSI using testicular sperm in NOA patients may pass genetic causes of impaired spermatogenesis to male offspring (particularly in Klinefelter syndrome and Y chromosome microdeletions), requiring genetic counselling discussion.

Post-procedural care involves scrotal support and ice pack application for 24–48 hours, analgesics (paracetamol and NSAIDs), and avoidance of strenuous activity for 5–7 days. Surgical site review at 1–2 weeks confirms wound healing and monitors for haematoma. Testosterone levels are checked at 3–6 months after micro-TESE to assess any impact on Leydig cell function; testosterone replacement therapy is initiated if clinical hypogonadism develops.

Retrieved and cryopreserved sperm are labelled, stored, and linked to the patient's IVF/ICSI programme. Couples proceed to ICSI as soon as the female partner has completed ovarian stimulation. Follow-up discussions address: results of sperm retrieval (number and quality of sperm obtained), ICSI success rates, and — if retrieval failed — counselling regarding donor sperm options and psychological support. Male fertility preservation (sperm banking before cancer treatment) provides peace of mind regardless of SSR outcome.

PESA in the US costs USD 2,000–5,000; standard TESE USD 3,000–8,000; micro-TESE USD 8,000–15,000 for the procedure itself (excluding ICSI costs of USD 10,000–15,000 per cycle). NHS England covers surgical sperm retrieval and ICSI for eligible couples (male azoospermia is a funded indication in most ICSs). UK private costs are GBP 1,500–6,000 for SSR.

Medical tourism for surgical sperm retrieval and ICSI is well-established in India, Thailand, Turkey, Czech Republic, and Greece — with 40–65% cost savings. ICSI with micro-TESE costs USD 4,000–8,000 in India at specialist andrology centres. Patients should confirm the IVF laboratory's ICSI success rates, embryology accreditation, the andrologist's micro-TESE caseload, and cryo storage quality before international fertility treatment travel. Patients are advised to obtain itemised cost estimates from multiple providers and verify insurance coverage or national health system entitlements before proceeding. Medical tourism at accredited hospitals in India, Thailand, Turkey, or Mexico can reduce total procedure costs by 50–80% compared to US or UK pricing, with internationally trained specialists and comparable clinical outcomes for elective procedures.

Vasectomy reversal (vasovasostomy or vasoepididymostomy) is the preferred alternative to SSR for post-vasectomy OA in men wishing multiple future pregnancies, as natural conception becomes possible after successful reversal. Success rates (patency) of 70–90% for vasovasostomy within 10 years of vasectomy make this a cost-effective alternative to repeated IVF/ICSI cycles. For men who are confirmed unable to retrieve sperm (NOA with failed micro-TESE), donor sperm IUI or ICSI provides an alternative path to parenthood with high success rates. Adoption provides parenthood without any involvement of the male partner's genetics. Patients who prefer less invasive or pharmacological approaches should discuss all available options with their treating specialist, as the optimal choice varies with disease severity, patient age, comorbidities, and individual preference. Second opinions from specialists at high-volume centres can help clarify the most appropriate treatment path for complex presentations.